Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:psychotherapy
immunoglobulin therapy |
| gptkbp:abbreviation |
gptkb:IVIG
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alternativeTo |
subcutaneous immunoglobulin
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J06BA02
|
| gptkbp:contains |
pooled immunoglobulin G
|
| gptkbp:contraindication |
IgA deficiency with anti-IgA antibodies
|
| gptkbp:cost |
high
|
| gptkbp:derivedFrom |
human plasma
|
| gptkbp:discoveredIn |
1952
|
| https://www.w3.org/2000/01/rdf-schema#label |
Intravenous immunoglobulin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
modulation of immune system
neutralization of autoantibodies suppression of inflammatory mediators |
| gptkbp:monitors |
liver function tests
complete blood count vital signs renal function tests serum IgG levels |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
anaphylaxis
hemolysis transmission of infectious agents volume overload |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
headache chills allergic reactions renal dysfunction thromboembolic events aseptic meningitis |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
gptkb:dermatomyositis
gptkb:chronic_inflammatory_demyelinating_polyneuropathy gptkb:Kawasaki_disease gptkb:immune_thrombocytopenic_purpura gptkb:myasthenia_gravis gptkb:Guillain–Barré_syndrome multiple sclerosis autoimmune diseases lupus immunodeficiency disorders multifocal motor neuropathy severe infections in immunocompromised patients |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:J06BA02
|
| gptkbp:bfsLayer |
8
|